Last mentioned: Feb 24, 2026
Lawsuit Announced
Rosen Law Firm announces the filing of the class action lawsuit and lead plaintiff opportunity.
Teva Legal Victory
Teva Pharmaceutical Industries wins an appeals court ruling over generic versions of Corcept's Korlym.
Class Period Ends
The cutoff date for the class action, often coinciding with a corrective disclosure.
Class Period Begins
The start date for the alleged period of securities fraud and misleading statements.
Corcept Therapeutics (NASDAQ: CORT) is the target of a class action lawsuit alleging securities fraud during a critical 14-month period of operational and legal shifts. The Rosen Law Firm is seeking lead plaintiffs for a class period that concluded in late 2025, amid intensifying pressure on the company's core product patents.
This page surfaces every story mentioning Corcept Therapeutics Incorporated across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Corcept Therapeutics Incorporated was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |